Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency

• Published in: Thrombosis and haemostasis Vol. 118; no. 3; pp. 451 - 460
• Main Authors: Carcao, Manuel, Altisent, Carmen, Castaman, Giancarlo, Fukutake, Katsuyuki, Kerlin, Bryce A., Kessler, Craig, Lassila, Riitta, Nugent, Diane, Oldenburg, Johannes, Garly, May-Lill, Rosholm, Anders, Inbal, Aida
• Format: Journal Article
• Language: English
• Published: Stuttgart Schattauer GmbH 01.03.2018
• Subjects: Coagulation and Fibrinolysis; congenital FXIII deficiency; prophylaxis; safety; recombinant FXIII-A; surgery

Abstract Recombinant factor XIII-A 2 (rFXIII-A 2 ) was developed for prophylaxis and treatment of bleeds in patients with congenital FXIII A-subunit deficiency. mentor™2 (NCT00978380), a multinational, open-label, single-arm, multiple-dosing extension to the pivotal mentor™1 trial, assessed long-ter...